Balaji Amines Limited, a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines,Ethyl Amines, Derivatives of Amines and other Specialty Chemicals, has posted its consolidated Q3 FY25 net profit at Rs. 31 crore as compared to Rs. 56 crore in Q3 FY24. Revenue from Operations for Q3FY25 stood at Rs. 321 crore, as compared to Rs. 392 crore in Q3 FY24. The same was at Rs. 356 crore in Q2 FY25. 

EBITDA for Q3FY25 was Rs. 54 crore, as compared to Rs. 70 crore in Q2FY25 and Rs. 83 crore in Q3FY24. EBITDA margin for Q3FY24 stood at 17% as against 20% in Q2FY25 and 21% in Q3FY24.

Commenting on the performance, D. Ram Reddy, Managing Director, said, “During Q3 FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum.

Additionally, the utilization of expanded capacities will contribute to margin enhancement, as some of our products progress through the final approval stages with end-user industries.

This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers.

Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the fiscal year 2025-26. Our focus on inherent strengths and  competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.”